NEW YORK, Oct. 3, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law
firm, is investigating whether certain officers and directors of
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) breached
their fiduciary duties to shareholders.
According to a federal securities lawsuit, Amylyx insiders
caused the company to misrepresent or fail to disclose that (i)
RELYVRIO's commercial prospects were overstated; (ii) patients were
discontinuing treatment with RELYVRIO after six months; (iii) the
rate at which new patients were starting treatment with RELYVRIO
was decreasing; (iv) accordingly, RELYVRIO's prescription rate was
also overstated; (v) insiders attempted to hide the foregoing
negative trends from investors and the market by blocking analysts
from viewing RELYVRIO's prescription data; and (vi) as a result,
the Company's public statements were materially false and
misleading at all relevant times.
If you currently own Amylyx and purchased prior to
November 11, 2022
please contact Justin Kuehn,
Esq. here, by email at justin@kuehn.law, or call
(833) 672-0814. The consultation and case are free with no
obligation to you. Kuehn Law pays
all case costs and does not charge its investor clients.
Shareholders should contact the firm immediately as there may be
limited time to enforce your rights.
Why Your Participation Matters:
As a shareholder your voice matters, and by getting involved,
you contribute to the integrity and fairness of the financial
markets. Your investment. Your voice. Your
future.™
For additional information, please visit Shareholder Derivative
Litigation - Kuehn Law.
Attorney advertising. Prior results do not guarantee similar
outcomes.
Contacts:
Kuehn Law, PLLC
Justin Kuehn, Esq.
53 Hill Street, Suite 605
Southampton, NY 11968
justin@kuehn.law
(833) 672-0814
View original content to download
multimedia:https://www.prnewswire.com/news-releases/kuehn-law-encourages-investors-of-amylyx-pharmaceuticals-inc-to-contact-law-firm-302266922.html
SOURCE Kuehn Law, PLLC